ClinicalTrials.gg
RecruitingNCT05917587Updated Oct 28, 2026

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

An Early Phase 1 interventional study of Metformin Hydrochloride and placebo in Gestational Diabetes, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.

Planned enrollment
34th of 39
30 · median 112
Started
2024
with 2 others
Phase 1
Only one
of the 39
Registered
35th of 39
by date
Lead sponsor
1 of 39
Anna Stanhewicz, PhD

Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 34th largest by planned enrollment, is one of 3 that started in 2024, is the only one in phase 1, and was the 35th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing metformin in Diabetes, Gestational, or all of them as a file.
02

Study summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Read the detailed description

Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease. This study will give rise to a new line of research that will center around the goal of improving lifetime cardiovascular outcomes in women with a history of GDM.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had GDM. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, the investigators also draw blood from the subjects and isolate the inflammatory cells.

03

Conditions studied

  • Gestational Diabetes

Browse trials for

Keywords

  • gestational diabetes
  • postpartum
  • vascular
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥12 weeks and ≤5 years postpartum
  • history of GDM or healthy pregnancy

Exclusion criteria

Exclusion Criteria:

  • prediabetes or diabetes ( ≥5.7%)
  • current tobacco use
  • cardiovascular or metabolic disease
  • cardiovascular or metabolic medication
  • history of hypertension during pregnancy
  • current pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    metformin

    Drug: Metformin Hydrochloride

  • Placebo comparator
    placebo

    Other: placebo

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.

  • Otherplacebo

    12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.

06

What researchers measure

Primary outcomes

  1. blood flow response to acetylcholine

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine

    Time frame: baseline

  2. blood flow response to acetylcholine

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine

    Time frame: 1 week of treatment

  3. blood flow response to acetylcholine

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine

    Time frame: 6 weeks of treatment

  4. blood flow response to acetylcholine

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine

    Time frame: 12 weeks of treatment

  5. blood flow response to insulin

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin

    Time frame: baseline

  6. blood flow response to insulin

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin

    Time frame: 1 week of treatment

  7. blood flow response to insulin

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin

    Time frame: 6 weeks of treatment

  8. blood flow response to insulin

    cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. Percentage of nitric oxide-dependent dilation

    NO-dependent (%) cutaneous microvascular dilation response to acetylcholine

    Time frame: baseline

  2. Percentage nitric oxide-dependent dilation

    NO-dependent (%) cutaneous microvascular dilation response to acetylcholine

    Time frame: 1 week of treatment

  3. Percentage of nitric oxide-dependent dilation

    NO-dependent (%) cutaneous microvascular dilation response to acetylcholine

    Time frame: 6 weeks of treatment

  4. Percentage of nitric oxide-dependent dilation

    NO-dependent (%) cutaneous microvascular dilation response to acetylcholine

    Time frame: 12 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Findings from the primary studies will be published and submitted to PubMed Central in compliance with the NIH public access policy. These findings will also be made public through the clinicaltrial.gov record. The final data set will be stripped of any identifying data prior to release for sharing. We will make the data and any associated documentation available to users only under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes and not to identify any one individual participant; 2) a commitment to securing the data using appropriate computer technology; and 3) a commitment to destroying or returning the data after all analyses are completed.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 26, 2023
StartActual
Sep 11, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, responsible party and oversight details
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05917587
Lead sponsor
Anna Stanhewicz, PhD
Responsible party
Anna Stanhewicz, PhD (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Jun 26, 2023
Start date
Sep 11, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Anna Stanhewicz, PhD
Contact
anna-stanhewicz@uiowa.edu
3194671732
Anna Stanhewicz, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion